Objective In this study, we investigated the distribution of Peroxiredoxin II mRNA in follicles at all stages in mouse ovaries and mouse secondary oocytes(MII eggs) basing on our previous researches, to provide the morphological basis for exploring the effect of Peroxiredoxin II on oogenesis and oocyte maturation in the mouse. Methods To observe the distribution of Peroxiredoxin II mRNA in follicles at all stages in ovaries and the localization of Peroxiredoxin II mRNA in Germinal-Vesicle intact oocytes(GV oocytes) and MII eggs by in situ Hybridization. Results In situ hybridization of ovary section revealed that the signals for Peroxiredoxin II mRNA were undetectable in oocytes of primordial follicles, and moderate signals for Peroxiredoxin II mRNA were observed in oocytes of primary follicles. Moreover, strong signals for Peroxiredoxin II mRNA were evident in antral follicles. The signals for Peroxiredoxin II mRNA also existed in GV oocytes and MII eggs in vitro. The hybrid signals were stronger in GV oocytes than in MII eggs. In addition, the weak but consistent signals for Peroxiredoxin II mRNA were detected in follicular cells from primordial follicles to large antral follicles. Peroxiredoxin II mRNA was located in cytoplasm of oocytes and follicular cells, but not in nuclei.Conclusion These results suggested that Peroxiredoxin II might be involved in the regulation of oogenesis and oocyte matruation in the mouse.;

Objective To study the effect of Peroxiredoxin Ⅱ on development of mouse preimplantation embryos in vitro and to investigate the possible action of Peroxiredoxin Ⅱ on preimplantation embryonic development. Methods One-cell embryos collected from the oviduct of the superovulated mice were cultured in microdrops of medium for 48?h.The effect of peroxiredoxin Ⅱ antibody on the development of embryo in vitro was observed,and the percentage of embryos developing to 2-and 4-cell stage of embryos was used as evaluation criteria.With redox-sensitive fluorescence probe 2′,7′-dichlorodihydroflurescin diacete(DCFH-DA),reactive oxygen species(ROS) induced by Peroxiredoxin Ⅱ antibody was monitored in mouse embryos after 24?h culture by laser confocal scanning microscopy. Results The embryonic development rate from 2-cell stage to 4-cell stage was decreased significantly by Peroxiredoxin Ⅱ antibody in the dilution of 1∶100 and 1∶200,but Peroxiredoxin Ⅱ antibody had no inhibitive effect on development from 1-cell to 2-cell stage.Moreover,Peroxiredoxin Ⅱ antibody in the dilution of 1∶200 induced increase in the production of reactive oxygen species in mouse embryos from 24?h culture of one-cell embryo.Conclusion Peroxiredoxin Ⅱ antibody induced the generation of “2-cell block” by increasing the production of reactive oxygen species(ROS) in mouse embryos.These results also indicated that Peroxiredoxin Ⅱ may reduce or eliminate ROS in preimplantation embryos and promote the development of preimplantation embryos.;

Objective To study the distribution and sequence analysis of gonadotropin releasing hormone (GnRH) gene in cultured gastric parietal cells of rats. Methods The distribution of GnRH molecule and GnRH mRNA were observed out through immunohistochemical ABC methods and in situ hybridization methods in cultured gastric parietal cells of rats. After isolation of the total RNA from the parietal cells, RT PCR was conducted to obtain GnRH cDNA. Then, the products of PCR was purified, digested by the restriction enzyme of Hind Ⅲ and EcoR Ⅰ, and DNA fragments interests were cloned into pUC19 vector. The products of PCR were analyzed by sequenceing with Sanger's method after identified by PCR and digestion of restriction enzyme. Results Gastric parietal cells showed GnRH immunoreactivity, positive material was located in cytoplasm with negative nuclei. GnRH mRNA hybridized signals were also detected in cytoplasm with negative nuclei. The specific amplified band of GnRH mRNA was detected through agarose gel electrophoresis and gene sequence is identical to the GnRH which has been reported in rat hypothalamus.Conclusion Our data suggest that GnRH could be produced by gastric parietal cells of rats and may modulate physiological function of gastric parietal cells of rats.\;[

AIM and METHODS: After the fine carbon fiber powder was injected into the right subdural space of the mice, dynamic observation was carried out on their movement and histopathological changes. RESULTS: 1-52 weeks after the injecting, no neurological changes concerning with the implanting of the carbon fiber powder were found in the experimental mice. The fine carbon fiber extensively located on the inter surface of the dura mater membrane of the right temporalis and the out surface of pie mater. Only slight inflammatory cells reaction was found under optical microscopes. The degree of inflammation reaction are Grade Ⅱ 1 week after injection and was Grade Ⅰ 2 weeks after injection, inflammation was disappeared 4 weeks after injection. No obvious fiber membrane was found around the implanted materials. No significant differences were found between the experimental and the control group.CONCLUSION: It was showed that the carbon fiber shares excellent histocompatibility after injected into the subdural space and subarechnoid cavity of the right temple of mice.

Objective To explore the expression of serine/threonine kinase 15 (STK15) gene and its significance for papillary thyroid carcinoma. Methods SP immunohistochemical method was used to detect the expression of STK15 gene in 71 cases of papillary thyroid carcinoma and 45 cases nodular goiter tissue. Results The positive expression rates of STK15 gene in 71 cases of papillary thyroid carcinoma were 100%, and the adjacent of papillary thyroid carcinoma expressions of STK15 gene 8.5%, nodular goiter tissue of STK15 gene expression rates 24.4%. The expression of STK15 gene was positively correlated with that of STK15 gene in papillary thyroid carcinoma (P < 0.01). Conclusion High expression of STK15 gene is confirmed in papillary thyroid carcinoma. The detection of STK15 gene can provide valuable evidence for diagnosis of papillary thyroid carcinoma and evaluation of the malignant potential of nodular goiter.

INTRODUCTION: This technical note describes a new arthroscopic technique to repair the peripheral attachment lesion of the posterior horn of the medial meniscus. The operation was performed under arthroscopy using a standard anterior portal. SURGICAL TECHNIQUE: A FasT-Fix needle was inserted obliquely close to the tibial plateau and the first implant was inserted into the joint capsule depending on its bending angle underneath the meniscus. The second implant was inserted through 1/3 periphery of the meniscus into the meniscocapsular area. The pre-tied self-sliding knot was tensioned to achieve secure fixation of the posterior meniscal peripheral attachment at the original attachment point. MATERIALS AND METHODS: From August 2011 to February 2014, 23 knees were diagnosed as ramp lesion, underwent meniscal repair using FasT-Fix technique. RESULTS: All patients were followed up for average 14 months. The Lysholm score improved from preoperative 64.4+/-4.52 to postoperative 91.2+/-4.60. CONCLUSIONS: We believe that the FasT-Fix technique via the standard anterior portal can be a more convenient and less traumatic alternative for repair of the peripheral attachment lesion of the posterior horn of the medial meniscus in the anterior cruciate ligament deficient knee.
Animals ; Anterior Cruciate Ligament ; Architectural Accessibility ; Arthroscopy ; Horns ; Humans ; Joint Capsule ; Knee ; Menisci, Tibial ; Needles

INTRODUCTION: In Singapore, non-anaesthesiologists generally administer sedation during gastrointestinal endoscopy. The drugs used for sedation in hospital endoscopy centres now include propofol in addition to benzodiazepines and opiates. The requirements for peri-procedural monitoring and discharge protocols have also evolved. There is a need to develop an evidence-based clinical guideline on the safe and effective use of sedation by non-anaesthesiologists during gastrointestinal endoscopy in the hospital setting. METHODS: The Academy of Medicine, Singapore appointed an expert workgroup comprising 18 gastroenterologists, general surgeons and anaesthesiologists to develop guidelines on the use of sedation during gastrointestinal endoscopy. The workgroup formulated clinical questions related to different aspects of endoscopic sedation, conducted a relevant literature search, adopted Grading of Recommendations, Assessment, Development and Evaluation (GRADE) methodology and developed recommendations by consensus using a modified Delphi process. RESULTS: The workgroup made 16 recommendations encompassing 7 areas: (1) purpose of sedation, benefits and disadvantages of sedation during gastrointestinal endoscopy; (2) pre-procedural assessment, preparation and consent taking for sedation; (3) Efficacy and safety of drugs used in sedation; (4) the role of anaesthesiologist administered sedation during gastrointestinal endoscopy; (5) performance of sedation; (6) post-sedation care and discharge after sedation; and (7) training in sedation for gastrointestinal endoscopy for non-anaesthesiologists. CONCLUSION These recommendations serve to guide clinical practice during sedation for gastrointestinal endoscopy by non-anaesthesiologists in the hospital setting.
Conscious Sedation ; Endoscopy, Gastrointestinal ; Hospitals ; Humans ; Hypnotics and Sedatives ; Singapore

Background::There is a need for effective and safe therapies for psoriasis that provide sustained benefits. The aim of this study was to assess the efficacy and safety of tildrakizumab, an anti-interleukin-23p19 monoclonal antibody, for treating moderate-to-severe plaque psoriasis in Chinese patients.Methods::In this multi-center, double-blind, phase III trial, patients with moderate-to-severe plaque psoriasis were enrolled and randomly assigned (1:1) to receive subcutaneous tildrakizumab 100 mg or placebo at weeks 0 and 4. Patients initially assigned to placebo were switched to receive tildrakizumab at weeks 12, 16, and every 12 weeks thereafter. Patients in the tildrakizumab group continued with tildrakizumab at week 16, and every 12 weeks until week 52. The primary endpoint was the Psoriasis Area and Severity Index (PASI 75) response rate at week 12.Results::At week 12, tildrakizumab demonstrated significantly higher PASI 75 response rates (66.4% [73/110] vs. 12.7% [14/110]; difference, 51.4% [95% confidence interval (CI), 40.72, 62.13]; P <0.001) and Physician’s Global Assessment (60.9% [67/110] vs. 10.0% [11/110]; difference, 49.1% [95% CI, 38.64, 59.62]; P <0.001) compared to placebo. PASI 75 response continued to improve over time in both tildrakizumab and placebo-switching to tildrakizumab groups, reaching maximal efficacy after 28 weeks (86.8% [92/106] vs. 82.4% [89/108]) and maintained up to 52 weeks (91.3% [95/104] vs. 87.4% [90/103]). Most treatment-emergent adverse events were mild and not related to tildrakizumab. Conclusion::Tildrakizumab demonstrated durable efficacy through week 52 and was well tolerated in Chinese patients with moderate-to-severe plaque psoriasis.Trial registration::ClinicalTrials.gov, NCT05108766.